Clinical Trials Browser

Phase 1/2 × Non-Muscle Invasive Bladder Neoplasms × Clear all

NCT05710848 2026-05-27

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT05316155 2026-05-08

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06637423 2026-05-01

TroFuse-027

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT04752722 2026-04-30

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT03317158 2026-04-15

ADAPT-BLADDER

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07505615 2026-04-01

VG-INFUSE Tria

Phase 1/2 Completed

Non-Muscle Invasive Bladder Neoplasms

NCT02138734 2026-03-31

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Phase 1/2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT06704191 2026-03-30

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06800963 2026-03-27

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07445308 2026-03-03

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

Phase 1/2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT05544552 2026-01-12

SURF301

Phase 1/2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Urologic Neoplasms

NCT07122414 2025-08-14

A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07064863 2025-07-17

BCG-TIME

Phase 1/2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT03081858 2025-06-27

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

Phase 1/2 Completed

15 enrolled 16 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT04179162 2025-06-13

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

Phase 1/2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT04106115 2024-12-04

DURANCE

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04690699 2024-10-24

LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors

Phase 1/2 Terminated

4 enrolled 6 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06588179 2024-09-19

SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt

Phase 1/2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT05232136 2024-08-12

OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT01625260 2024-07-19

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Phase 1/2 Terminated

12 enrolled 13 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Recurrence

NCT03636256 2023-08-14

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

Phase 1/2 Completed

36 enrolled 18 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

NCT02371447 2023-04-13

VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer

Phase 1/2 Completed

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT00318643 2021-10-29

Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer

Phase 1/2 Completed

27 enrolled 14 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT02009332 2021-06-08

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

Phase 1/2 Completed

21 enrolled 11 charts

Non-Muscle Invasive Bladder Neoplasms

NCT03498196 2020-08-24

A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer

Phase 1/2 Terminated

1 enrolled 10 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03560479 2020-08-19

A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer

Phase 1/2 Unknown

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT03167151 2020-07-31

PemBla

Phase 1/2 Terminated

6 enrolled 12 charts

Non-Muscle Invasive Bladder Neoplasms

NCT03672240 2020-07-20

NMIBC

Phase 1/2 Completed

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT02007005 2015-05-06

Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer

Phase 1/2 Completed

Non-Muscle Invasive Bladder Neoplasms

NCT01939756 2013-09-11

Baobab

Phase 1/2 Completed

Non-Muscle Invasive Bladder Neoplasms, Lower Urinary Tract Symptoms

NCT00322699 2012-10-26

Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer

Phase 1/2 Completed

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Photosensitivity Disorders